SAN DIEGO — Patients with cirrhosis treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant reductions in a range of portal hypertension complications and all-cause ...

When used in everyday practice, sodium-glucose cotransporter 2 (SGLT2) inhibitors provide rapid and sustained benefits to patients with a recent heart failure (HF) hospitalization, a nationwide ...

Proportion of adult managed care organizations with availability varied from 24 to 100 percent for SGLT2 inhibitors, 0 to 99 percent for GLP-1 receptor agonists. (HealthDay News) — Many Medicaid ...

Sodium–glucose cotransporter-2 (SGLT2) inhibitors are an effective treatment for heart failure, chronic kidney disease, and type 2 diabetes, but increase the risk of diabetic ketoacidosis. Prescribing ...

TUESDAY, May 13, 2025 (HealthDay News) -- Patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) preoperatively have a slightly increased risk for postoperative euglycemic ketoacidosis ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

Merck and Pfizer are hoping to cover all bases if they get their latest SGLT2 inhibitor to market. There is a crowd of already-approved rivals, but the companies are doing their best to ensure ...

New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...

Individuals with type 2 diabetes receiving either metformin or sodium-glucose cotransporter 2 inhibitors (SGLT2) inhibitors experience comparable rates of incident gout, according to study findings ...